Several studies have analyzed the efficacy of innovative therapeutic strategies for CeD, among which the effect of monoclonal antibodies neutralizing IL-15 protein on duodenal biopsies from CeD patients by an ex vivo approach, uncovering relevant insights into the pathogenesis of the disease [15]. This evidence concerns the gene IL15 and cranioectodermal dysplasia.